[go: up one dir, main page]

WO2006005469A3 - Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) - Google Patents

Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) Download PDF

Info

Publication number
WO2006005469A3
WO2006005469A3 PCT/EP2005/007175 EP2005007175W WO2006005469A3 WO 2006005469 A3 WO2006005469 A3 WO 2006005469A3 EP 2005007175 W EP2005007175 W EP 2005007175W WO 2006005469 A3 WO2006005469 A3 WO 2006005469A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
gcgr
therapeutics
diagnostics
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/007175
Other languages
French (fr)
Other versions
WO2006005469A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2006005469A2 publication Critical patent/WO2006005469A2/en
Publication of WO2006005469A3 publication Critical patent/WO2006005469A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human GCGR which is associated with the cardiovascular diseases, cancer, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GCGR as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007175 2004-07-15 2005-07-02 Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) Ceased WO2006005469A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016639.9 2004-07-15
EP04016639 2004-07-15

Publications (2)

Publication Number Publication Date
WO2006005469A2 WO2006005469A2 (en) 2006-01-19
WO2006005469A3 true WO2006005469A3 (en) 2006-04-06

Family

ID=35285269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007175 Ceased WO2006005469A2 (en) 2004-07-15 2005-07-02 Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)

Country Status (1)

Country Link
WO (1) WO2006005469A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845802B2 (en) 2018-07-27 2023-12-19 Ngm Biopharmaceuticals, Inc. Combination therapy with a glucagon receptor (GCGR) antibody and an anti-CD3 antibody

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002668A1 (en) * 2006-09-20 2008-05-09 Amgen Inc ANTIGEN UNION PROTEIN THAT JOINS THE HUMAN GLUCAGON RECEIVER; NUCLEIC ACID THAT CODIFIES IT; METHOD OF PRODUCTION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT OR PREVENT TYPE 2 DIABETES.
AR070844A1 (en) 2008-03-27 2010-05-05 Lilly Co Eli FABGMENT FAB OR HUMANIZED MONOCLONAL ANTIBODY UNDERSTANDING THE FAB FRAGMENT, AND ITS USE FOR THE MANUFACTURE OF AN ANTAGONIST MEDICINAL PRODUCT OF THE GLUCAGON RECEPTOR POLYPEPTIDE FOR THE TREATMENT OR PREVENTION OF TYPE 1 OR 2 DIABETES
JP2011523052A (en) 2008-05-23 2011-08-04 アミリン・ファーマシューティカルズ，インコーポレイテッド GLP-1 receptor agonist bioassay
CN108348582B (en) 2015-09-04 2023-04-14 瑞美德生物医药科技有限公司 Methods for treating heart failure using glucagon receptor antagonist antibodies
US10995145B2 (en) 2017-01-27 2021-05-04 Ngm Biopharmaceuticals, Inc. Antibodies which bind human glucagon receptor
EP3708577B1 (en) * 2017-11-06 2024-09-04 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue glp-1r/gcgr dual-target agonist peptide

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. CRESPEL, F. DE BOISVILLIERS, L. GROS, AND A. KERVAN: "Effects of Glucagon and Glucagon like Peptide-1(7-36) Amide on C cells from Rat Thyroid and Medulary Thyroid carcinoma CA-77 Cell line", ENDOCRINOLOGY, vol. 137, no. 9, 1996, pages 3674 - 3680, XP002354960 *
DALLAS-YANG Q ET AL: "Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 501, no. 1-3, 6 October 2004 (2004-10-06), pages 225 - 234, XP004587613, ISSN: 0014-2999 *
DJURIC S W ET AL: "GLUCAGON RECEPTOR ANTAGONISTS FOR THE TREATMENT OF TYPE II DIABETES: CURRENT PROSPECTS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 3, no. 11, November 2002 (2002-11-01), pages 1617 - 1623, XP001146198, ISSN: 0967-8298 *
EVA BRAND, LISE BANKIR, PIERRE-FRANÇOIS PLOUIN, FLORENT SOUBRIER: "Glucagon Receptor Gene Mutation (Gly40Ser) in Human Essential Hypertension The Pegase study", HYPERTENSION, July 1999 (1999-07-01), XP002354964 *
JEAN-CLAUDE MARIE,CLAUDINE BOISSARD, GUNNAR SKOGLUND, GABRIEL ROSSELIN, BERNADETTE BREANT: "Glucanon Acts Through Its Own Receptors in the Presence of Functional Glucagon-like Peptide-1 Receptors on Hamster Insulinoma", ENDOCRINOLOGY, vol. 137, no. 10, 1996, pages 4108 - 4114, XP002354962 *
MARGARET A. CASCIERI ET AL: "Characterization of a novel, non-Peptidyl Anatgonist of the human Glucanon Receptor", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 13, 26 March 1999 (1999-03-26), pages 8694 - 8697, XP002218972 *
MICHAEL SVOBODA, LAURENCE PORTOIS AND WILLY J. MALAISSE, MOLECULAR GENETICS AND METABOLISM, vol. 68, 1999, pages 258 - 267, XP002354963 *
SCHMIDT-KASTNER R ET AL: "GENES NEWLY CONNECTED TO BRAIN ISCHEMIA BY DNA MICROARRAY ANALYSIS AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN RAT.", SOCIETY FOR NEUROSCIENCE - ABSTRACT VIEWER AND ITINERARY PLANNER - PROGRAM NO. 694.6, 2002, Washington DC, XP002354961, Retrieved from the Internet <URL:http://sfn.scholarone.com/itin2002/main.html?new_page_id=126&abstract_id=4147> [retrieved on 20051104] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845802B2 (en) 2018-07-27 2023-12-19 Ngm Biopharmaceuticals, Inc. Combination therapy with a glucagon receptor (GCGR) antibody and an anti-CD3 antibody

Also Published As

Publication number Publication date
WO2006005469A2 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2006005470A3 (en) Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005114210A8 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2006005461A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 27 (gpr27)
WO2006008003A3 (en) Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
WO2006010515A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase